CompletedNot Applicable

Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell

South Korea30 participantsStarted 2014-01-01

Plain-language summary

Purpose:Development of novel strategy for treatment of anterior cruciate ligament (ACL) injury using stem cell.

Age range20 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age 20\~50
✓. Lachman test grade II,III or Pivot shift test grade I,II,III or ACL rupture in MRI
✓. prothrombin time (PT) (INR) \<1.5, activated partial thromboplastin time (aPTT) \<1.5 x control
✓. Creatinine ≤2.0 ㎎/㎗, protein uria(dipstick) ≤ trace
✓. Bilirubin ≤2.0 ㎎/㎗, aspartate aminotransferase (AST) /Alanine Aminotransferase (ALT) ≤100 IU/L
✓. No surgery and radiation therapy in recent 6 weeks
✓. No pregnancy
✓. No combine ligament instability ≥ grade II in physical examination (grade 0: none, grade I: 0\~5mm, grade II: 5\~10mm, grade III: \>10mm)

Bone formation on interface between bone tunnel and graft

Timeframe: Changes at 12 week, 24 week, 48 week after surgery

NCT IDNCT02755376

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-04-28